Authors: Ludovic Jondreville, Maud D’Aveni, Hélène Labussière-Wallet, Amandine Le Bourgeois, Alban Villate, Ana Berceanu, Silvia-Maria Bezsera, Anne Thiebaut, Marion Boissard-Simonet, Marlène Legrand, Jérôme Cornillon, Marie-Thérèse Rubio, Patrice Chevallier, Stéphanie Nguyen
Published: 2022-11-28
DOI: 10.1186/s13045-022-01387-0
Source: Full article
AbstractSince the emergence of the Omicron variant of SARS-CoV-2, though considered less virulent, hospitalization and death rates among immunocompromised patients remain high, especially for poor responders to vaccination. We conducted a retrospective multicentric study to evaluate pre-exposure prophylaxis with AZD7442 (tixagevimab/cilgavimab) for preventing COVID-19 in adult allogeneic hematopoietic stem cell transplant (allo-HSCT) recipients. Among the 161 patients of our cohort, 22 (14%) contracted COVID-19 after a median follow-up of 105 days, but no severe form was observed. Only one major adverse event was reported: an acute coronary syndrome, resolved without sequelae. Pending randomized controlled trial results, our data support the use of AZD7442 as pre-exposure prophylaxis for COVID-19 during Omicron wave in allo-HSCT patients who failed to develop humoral immunity to vaccination, to prevent severe and potentially lethal forms of SARS-CoV-2 infection.